The prognostic significance of miR-150 in a multivariate analysis
| . | Multivariate Cox regression of OS . | Multivariate Cox regression of TFS . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 108, number of events = 22* . | n = 76, number of events = 49* . | ||||||||||||
| Nondelayed entry model . | Delayed entry model . | Nondelayed entry model . | Delayed entry model . | ||||||||||
| Variable . | HR . | CI . | P . | HR . | CI . | P . | HR . | CI . | P . | HR . | CI . | P . | |
| miR-150 (≤ vs > median) | 9.6 | 1.6-57.8 | .01 | 6.0 | 1.2-30.8 | .03 | 2.4 | 1.2-4.7 | .014 | 3.6 | 1.8-7.4 | .0004 | |
| IGHV (unmut. vs mut.) | 5.9 | 0.4-85.5 | .19 | 2.4 | 0.1-40.0 | .54 | 1.3 | 0.5-3.5 | .64 | 0.3 | 0.1-1.2 | .099 | |
| ZAP-70 (pos. vs neg.) | 8.9 | 1.5-53.6 | .02 | 28.5 | 2.1-78.3 | .01 | 2.4 | 0.8-7.5 | .11 | 5.5 | 1.6-19.2 | .008 | |
| CD38 (pos. vs neg.) | 1.7 | 0.5-5.5 | .37 | 1.7 | 0.5-5.8 | .41 | 3.2 | 1.4-7.1 | .004 | 3.0 | 1.2-7.5 | .02 | |
| Gender (male vs female) | 2.6 | 0.7-9.5 | .17 | 2.8 | 0.7-10.9 | .14 | 2.1 | 0.9-4.6 | .07 | 2.0 | 0.9-4.7 | .1 | |
| Rai stage | I vs 0 | 5.2 | 0.8-35.8 | .09 | 2.3 | 0.3-18.1 | .42 | 2.9 | 1.3-6.6 | .01 | 1.1 | 0.5-2.6 | .79 |
| II vs 0 | 6.6 | 0.7-63.5 | .10 | 5.0 | 0.4-55.2 | .19 | 7.8 | 2.8-21.6 | .0001 | 2.6 | 0.9-7.3 | .07 | |
| ≥III vs 0 | 3.4 | 0.5-21.0 | .19 | 2.5 | 0.4-15.7 | .34 | 4.4 | 0.8-24.3 | .09 | 2.2 | 0.4-12.6 | .39 | |
| Age (> vs ≤ median) | 2.4 | 0.6-9.2 | .22 | 1.8 | 0.4-7.8 | .46 | 0.5 | 0.3-1.0 | .05 | 0.7 | 0.4-1.4 | .28 | |
| del17p13 | 4.0 | 0.8-19.5 | .09 | 3.0 | 0.5-16.3 | .21 | 1.4 | 0.5-4.3 | .52 | 3.2 | 1.1-9.5 | .03 | |
| del11q23 | 1.2 | 0.3-4.4 | .81 | 1.0 | 0.3-3.4 | .97 | 1.2 | 0.5-2.9 | .75 | 1.1 | 0.4-2.8 | .9 | |
| . | Multivariate Cox regression of OS . | Multivariate Cox regression of TFS . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 108, number of events = 22* . | n = 76, number of events = 49* . | ||||||||||||
| Nondelayed entry model . | Delayed entry model . | Nondelayed entry model . | Delayed entry model . | ||||||||||
| Variable . | HR . | CI . | P . | HR . | CI . | P . | HR . | CI . | P . | HR . | CI . | P . | |
| miR-150 (≤ vs > median) | 9.6 | 1.6-57.8 | .01 | 6.0 | 1.2-30.8 | .03 | 2.4 | 1.2-4.7 | .014 | 3.6 | 1.8-7.4 | .0004 | |
| IGHV (unmut. vs mut.) | 5.9 | 0.4-85.5 | .19 | 2.4 | 0.1-40.0 | .54 | 1.3 | 0.5-3.5 | .64 | 0.3 | 0.1-1.2 | .099 | |
| ZAP-70 (pos. vs neg.) | 8.9 | 1.5-53.6 | .02 | 28.5 | 2.1-78.3 | .01 | 2.4 | 0.8-7.5 | .11 | 5.5 | 1.6-19.2 | .008 | |
| CD38 (pos. vs neg.) | 1.7 | 0.5-5.5 | .37 | 1.7 | 0.5-5.8 | .41 | 3.2 | 1.4-7.1 | .004 | 3.0 | 1.2-7.5 | .02 | |
| Gender (male vs female) | 2.6 | 0.7-9.5 | .17 | 2.8 | 0.7-10.9 | .14 | 2.1 | 0.9-4.6 | .07 | 2.0 | 0.9-4.7 | .1 | |
| Rai stage | I vs 0 | 5.2 | 0.8-35.8 | .09 | 2.3 | 0.3-18.1 | .42 | 2.9 | 1.3-6.6 | .01 | 1.1 | 0.5-2.6 | .79 |
| II vs 0 | 6.6 | 0.7-63.5 | .10 | 5.0 | 0.4-55.2 | .19 | 7.8 | 2.8-21.6 | .0001 | 2.6 | 0.9-7.3 | .07 | |
| ≥III vs 0 | 3.4 | 0.5-21.0 | .19 | 2.5 | 0.4-15.7 | .34 | 4.4 | 0.8-24.3 | .09 | 2.2 | 0.4-12.6 | .39 | |
| Age (> vs ≤ median) | 2.4 | 0.6-9.2 | .22 | 1.8 | 0.4-7.8 | .46 | 0.5 | 0.3-1.0 | .05 | 0.7 | 0.4-1.4 | .28 | |
| del17p13 | 4.0 | 0.8-19.5 | .09 | 3.0 | 0.5-16.3 | .21 | 1.4 | 0.5-4.3 | .52 | 3.2 | 1.1-9.5 | .03 | |
| del11q23 | 1.2 | 0.3-4.4 | .81 | 1.0 | 0.3-3.4 | .97 | 1.2 | 0.5-2.9 | .75 | 1.1 | 0.4-2.8 | .9 | |
CI, confidence interval (of 95%); HR, hazard ratio. The values in row miR-150 are boldfaced to highlight results for this gene of interest.
Analysis includes only samples with known FISH status and obtained before the last day of follow up for OS analysis (108/168) or before first therapy for TFS analysis (76/168). The multivariate analysis for samples including those with unknown FISH status obtained before the last day of follow-up for OS analysis (154/168) or before first therapy for TFS analysis (107/168) is provided in supplemental Table 4.